Scotland approves Ipsen’s cabozantinib to treat kidney cancer
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
List view / Grid view
News
Leading European health start ups join forces to better serve insurers
Insurance companies are increasingly embracing innovative mobile solutions with the aim of helping their members live healthier lives and access quality care conveniently and efficiently.
One footprint, multiple set-ups with Syrris’ Orb Pilot
Syrris’ Orb Pilot jacketed reactor system is proving a big hit for chemical process scale-up, offering multiple set-ups in a single footprint, designed around your needs...
Drug costs vary by more than 600% in study of 10 high-income countries
In a study of 10 high-income countries with universal health care, costs for prescription drugs in 6 of the largest categories varied by more than 600%.
Ashfield appoints new regional presidents in US and Japan
Ashfield welcomes Greg Flynn to the US and Mick O’Leary to Japan…
Artificial intelligence to usher in new era of drug safety automation
Genpact’s new Pharmacovigilance Artificial Intelligence solution promises to transform drug safety data management and reporting…
What does a hung parliament mean for UK healthcare?
Hitesh Dodhia, Superintendent Pharmacist at Pharmacy Outlet, discusses the announcement of a hung parliament and what it means for UK healthcare...
Aptar Pharma extends nasal pump manufacturing capabilities
Aptar Pharma has announced the installation of manufacturing capacity for its child-resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.
Q BioMed to commercialise non-narcotic metastatic cancer pain drug
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
MSD investment confirms thriving biopharmaceutical hub
MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector...
Asia-Pacific asthma market will hit $6 billion by 2023
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
Vertex in long-term reimbursement agreement with ROI for CF medicines
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
Global study sets new standard to personalise chemotherapy
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
Lynparza significantly reduces risk of disease worsening or death
8 June 2017 | By Niamh Marriott, Junior Editor
AstraZeneca's positive results from its trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival...
Novartis & Bristol-Myers Squibb to collaborate on cancer treatments
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
